Currently, there are 949.38M common shares owned by the public and among those 850.67M shares have been available to trade.
The company’s stock has a 5-day price change of -12.64% and -23.45% over the past three months. LLY shares are trading 24.75% year to date (YTD), with the 12-month market performance up to 23.52% higher. It has a 12-month low price of $561.65 and touched a high of $972.53 over the same period. LLY has an average intraday trading volume of 3.22 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.55%, -17.26%, and -12.94% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Lilly(Eli) & Co (NYSE: LLY) shares accounts for 72.76% of the company’s 949.38M shares outstanding.
It has a market capitalization of $655.19B and a beta (3y monthly) value of 0.42. The stock’s trailing 12-month PE ratio is 79.55, while the earnings-per-share (ttm) stands at $9.14. The company has a PEG of 2.41 and a Quick Ratio of 0.97 with the debt-to-equity ratio at 2.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.21% over the week and 3.06% over the month.
Earnings per share for the fiscal year are expected to increase by 109.82%, and 69.84% over the next financial year. EPS should grow at an annualized rate of 33.00% over the next five years, compared to 13.74% over the past 5-year period.
Looking at the support for the LLY, a number of firms have released research notes about the stock. Wolfe Research stated their Outperform rating for the stock in a research note on November 15, 2024, with the firm’s price target at $1000. Bernstein coverage for the Lilly(Eli) & Co (LLY) stock in a research note released on October 17, 2024 offered a Outperform rating with a price target of $1100. Citigroup was of a view on September 13, 2024 that the stock is Buy, while Deutsche Bank gave the stock Buy rating on August 12, 2024, issuing a price target of $1025. DZ Bank on their part issued Hold rating on February 21, 2024.
